Alzheimer's disease (AD) is the most common form of dementia among the elderly, and the incidence of AD increases with aging. 1,2 AD is a severe neurodegenerative disorder defined histologically by the presence of senile plaques containing amyloid-β (Aβ). Although the major pathological hallmark of AD is the extracellular deposits of Aβ and Aβ plays a central role in the pathogenesis of cognitive impairment in AD, various vascular risk factors are also associated with the prevalence of AD and cognitive dysfunction in AD. [1] [2] [3] Recent clinical and experimental findings show that ischemic stroke is associated with the increased risk of AD and dementia. 1, 4, 5 It is estimated that AD is 3 times more likely to precipitate in old age after a transient ischemia attack. Thus, cerebral ischemia may exacerbate dementia and worsen outcomes in AD patients. However, the mechanism underlying the onset and progression of AD by cerebral ischemia remains to be elucidated. There have been conflicting findings concerning the influence of transient short duration of cerebral ischemia on AD. [6] [7] [8] Renin-angiotensin system plays a central role in the pathophysiology of hypertension, cardiovascular, and renal diseases. 9 A growing body of evidence suggests that reninangiotensin system may be involved in the pathophysiology of AD. 10, 11 Recent prospective cohort analysis 12 and nested case-control analysis 5 show that patients prescribed ARB have lower incidence and lower rate of progression to dementia and AD. Population-based cohort study 13 also show that patients exposed to ARB in high vascular risk of population experienced lower risk of dementia and AD in individuals. Thus, these findings suggest that ARB may reduce the risk of AD, although prospective randomized clinical trial is required to define these interesting findings.
Furthermore, previous preclinical studies show that ARBs can ameliorate cognitive impairment in AD mouse model (APP23 mice), 14 type-2 diabetic mice, 15 or mice with chronic cerebral hypoperfusion 16 and also protect against brain injury in brain ischemia animal model. 7, [17] [18] [19] [20] [21] However, to our knowledge, the effect of ARB on combined model of AD and brain ischemia remains to be determined.
In the present study, by using 5XFAD mice, a useful mouse model of AD, we hypothesized that (i) transient brief duration of cerebral ischemia can exert significant detrimental effects on AD mice and (ii) ARB posttreatment can improve cognitive impairment and brain injury in AD mice subjected to transient brief cerebral ischemia.
We obtained the evidence that transient brief cerebral ischemia significantly enhanced cognitive impairment and brain injury in AD mice, through angiotensin AT1 receptor.
MATERIALS AND METHODS

Ethics statement
All experiments were approved by the Kumamoto University Committee for Laboratory Animal Care and Use. All of the experimental procedures were performed in accordance with guidelines on animal science.
Transient brief global cerebral ischemia by bilateral common carotid artery occlusion
Male 5XFAD mice and C57BL/6J mice (wild-type mice) were anesthetized with 2% isoflurane and maintained with 1.5% isoflurane via a facemask. The rectal temperature was controlled at 37.0 ± 0.5 °C during surgery with a feedbackregulated heating pad. Transient brief cerebral ischemia was induced by bilateral common carotid artery occlusion (BCCAO). Briefly, BCCAO were isolated and occluded with a microvascular clip. To prepare mouse brain ischemia model, we had previously performed 17 minutes of BCCAO in our previous report, 22 since 17 minutes of BCCAO is generally used as a mouse brain ischemia model. Based on our previous report, 22 to perform transient short duration of cerebral ischemia, BCCAO was performed for 17 minutes, and then, the clips were removed to allow reperfusion. There was no significant difference in cerebral blood flow during BCCAO between 5XFAD and wild-type mice (data not shown), indicating comparable degree of brain ischemia between both strains.
Experimental protocol
Experimental protocol is shown in Figure 1 . Ten-monthold male 5XFAD mice were subjected to 17 minutes of BCCAO or sham operation, by the method described above, and then randomly divided into 3 groups, including (i) sham operation group, (ii) BCCAO group, and (iii) BCCAO + olmesartan group. In BCCAO + olmesartan group, olmesartan posttreatment was started at 1 day after transient cerebral ischemia by BCCAO. In the present study, the dose of olmesartan was 1 mg/kg/day, since such a dose of olmesartan is reported to ameliorate cognitive impairment in a mouse model of AD alone (APP23 mice). 14 Olmesartan at 1 mg/kg/ day was orally given to 5XFAD mice by gastric gavage for 5 weeks. Wild-type mice were divided into (i) sham operation group and (ii) BCCAO group by the method described above. Blood pressure was measured at 0, 2, and 5 weeks after transient cerebral ischemia by BCCAO. Passive avoidance test, open-field test, rotarod test, water maze test, and cerebral vascular reactivity to acetazolamide were estimated at 3, 3, 3, 4, and 5 weeks, respectively, after transient cerebral ischemia. Mice were sacrificed at 5 weeks after transient cerebral ischemia, and brain were immediately removed for analysis of various parameters as described below.
The detailed Materials and Methods are described in Supplementary Information.
RESULTS
Water maze test and shuttle avoidance test of wild-type mice and 5XFAD mice
As shown by escape latency of the hidden platform test on water maze test in Figure 2a , escape latency of 5XFAD mice subjected to BCCAO was greater than that of 5XFAD mice received sham operation (P < 0.01) and was also greater than that of wild-type mice subjected to BCCAO (P < 0.05). Escape latency of 5XFAD mice subjected to both BCCAO and olmesartan posttreatment was significantly smaller than that of 5XFAD subjected to only BCCAO (P < 0.01), and did not differ from that of sham-operated wild-type mice. Figure 2b indicates cumulative escape latency of water maze test in each group. Cumulative escape latency was significantly larger in 5XFAD subjected to BCCAO than in wildtype mice subjected to BCCAO (P < 0.05), and olmesartan treatment significantly reduced cumulative escape latency in BCCAO-subjected 5XFAD mice (P < 0.05). As shown by the probe test in Figure 2c , BCCAO significantly reduced number of platform crossings in 5XFAD mice (P < 0.01), and olmesartan posttreatment significantly prevented BCCAO-induced reduction of number of platform crossings (P < 0.01). As shown by escape latency in the visible test on water maze test in Figure 3 , there was no significant difference in escape latency between all groups of 5XFAD or wild-type mice.
As shown by passive avoidance test in Figure 4 , latency on day 3 of BCCAO group of 5XFAD mice was significantly smaller than that of sham group of 5XFAD (P < 0.05). Latency on day 3 of BCCAO + olmesartan group of 5XFAD mice was significantly larger than that of BCCAO group of 5XFAD (P < 0.01) and was comparable to that of sham operated wild-type mice.
Open-field test of wild-type mice and 5XFAD mice
As shown by open-field test in Figure 5 , time in central area was not different between sham groups of wild-type mice and 5XFAD mice. Time in central area in BCCAO group of 5XFAD mice was significantly smaller than that in sham group of 5XFAD mice (P < 0.05). However, olmesartan treatment of BCCAO group of 5XFAD mice significantly increased time in central area (P < 0.01) to comparable levels to sham groups of wild-type mice and 5XFAD mice. There was no significant difference in migration distance between all groups of 5XFAD mice.
Rotarod test of wild-type mice and 5XFAD mice
As shown in Figure 6 , time to the fall from the drum on rotarod test did not differ among all groups of 5XFAD and wild-type mice. Values are means ± SEM. n = 11 in WT-Sham, n = 12 in WT-BCCAO, n = 10 in 5XFAD-Sham, n = 10 in 5XFAD-BCCAO, n = 10 in 5XFAD-BCCAO + Olm. Statistical analysis was performed by 2-factor ANOVA with repeated measures followed by a post hoc Tukey's multiple comparison test between each group. Abbreviations: ANOVA, analysis of variance; BCCAO, group subjected to bilateral common carotid arterial occlusion; BCCAO + Olm, group subjected to bilateral common carotid arterial occlusion and treated with olmesartan; Sham, sham-operated group; WT, wild-type.
Hippocampal and cortical neuronal cell number of wildtype mice and 5XFAD mice
As shown in Figure 7 , neuronal cell number in hippocampal intermedial CA1 region was significantly less in BCCAO group of 5XFAD mice than that in sham group of 5XFAD mice (P < 0.01), sham group of wild-type mice (P < 0.01), and BCCAO group (P < 0.01) of wild-type mice. Olmesartan posttreatment significantly prevented the decrease in neuronal cell number in hippocampal intermedial CA1 of 5XFAD mice received BCCAO (P < 0.05).
On the other hand, as shown in Figure 8 , BCCAO did not significantly affect cortical neuronal cell number in wild-type mice or 5XFAD mice. There was no significant difference in cortical neuronal cell number among the 3 groups of 5XFAD mice.
Blood-brain barrier of wild-type mice and 5XFAD mice
As shown in Figure 9 , there was no significant difference in cerebral IgG leakage between sham group of wild-type mice and 5XFAD mice. BCCAO significantly increased cerebral IgG leakage in 5XFAD mice (P < 0.01) but BCCAO failed to increase IgG leakage in wild-type mice. Olmesartan postadministration significantly prevented BCCAO-induced increase in cerebral IgG leakage in 5XFAD mice (P < 0.01). Values are means ± SEM. n = 11 in WT-Sham, n = 12 in WT-BCCAO, n = 10 in 5XFAD-Sham, n = 10 in 5XFAD-BCCAO, n = 10 in 5XFAD-BCCAO + Olm. In (a), statistical significance was tested with 1-way ANOVA followed by a post hoc Tukey's multiple comparison test. In (b), statistical significance was tested with Kruskal-Wallis test followed by a post hoc Dunn's multiple comparison test between each group. Abbreviations: ANOVA, analysis of variance; BCCAO, group subjected to bilateral common carotid arterial occlusion; BCCAO + Olm, group subjected to bilateral common carotid arterial occlusion and treated with olmesartan; Sham, sham-operated group; WT, wild-type. Values are means ± SEM. n = 11 in WT-Sham, n = 12 in WT-BCCAO, n = 10 in 5XFAD-Sham, n = 10 in 5XFAD-BCCAO, n = 10 in 5XFAD-BCCAO + Olm. In days 1 and 3, statistical significance was tested with Kruskal-Wallis test followed by a post hoc Dunn's multiple comparison test between each group. Abbreviations: BCCAO, group subjected to bilateral common carotid arterial occlusion; BCCAO + Olm, group subjected to bilateral common carotid arterial occlusion and treated with olmesartan; Sham, sham-operated group; WT, wild-type.
Cerebral oxidative stress of wild-type mice and 5XFAD mice
As shown in Figure 10a , no difference was found in hippocampal superoxide levels between sham groups of wildtype mice and 5XFAD mice. However, BCCAO tended to increase hippocampal superoxide levels in 5XFAD, and hippocampal superoxide levels in BCCAO group of 5XFAD were significantly greater than those in sham group of wildtype mice (P < 0.05). Olmesartan postadministration significantly prevented BCCAO-induced increase in hippocampal superoxide levels in 5XFAD mice (P < 0.05).
As shown in Figure 10b , olmesartan postadministration significantly decreased cortical superoxide levels in 5XFAD mice subjected to BCCAO (P < 0.01).
Cerebral vascular reactivity of wild-type mice and 5XFAD mice
As shown in Figure 11 , the increase in cerebral blood flow induced by acetazolamide was similar between all groups of wild-type mice and 5XFAD mice. As shown in Figure 12 , there was no significant difference in the amounts of cerebral soluble Aβ 1-42 or insoluble Aβ 1-42 among sham, BCCAO, and BCCAO + olmesartan groups of 5XFAD.
Blood pressure of wild-type mice and 5XFAD mice
As shown in Figure 13 , blood pressure did not differ throughout the treatment among sham, BCCAO, and BCCAO + olmesartan groups of 5XFAD mice. 
DISCUSSION
Cerebral ischemia is responsible for the progression of cognitive impairment in AD and increases the prevalence of AD. 1, 4, 23, 24 However, the role of cerebral ischemia in the pathophysiology of cognitive impairment in AD is poorly understood. Furthermore, the effect of ARB on combined animal model of AD and brain ischemia is unclear. The major findings of this work were as follows: (i) transient brief cerebral ischemia caused cognitive impairment (learning impairment) and brain injury in AD mice to a greater extent than in wildtype mice and (ii) angiotensin AT1 receptor was responsible for brief cerebral ischemia-induced cognitive impairment and brain injury of AD mouse, through blood-brain barrier disruption and oxidative stress. Thus, our present work provided a novel evidence for the important role of angiotensin in cerebral ischemia-induced cognitive impairment in AD.
There have been controversial findings regarding the influence of brief brain ischemia on AD animal model. [6] [7] [8] In the present study, to examine whether transient brief cerebral ischemia causes cognitive impairment and brain injury in AD mice more than in wild-type mice, we compared the effect of brief cerebral ischemia on cognitive function and brain injury between 5XFAD mice and wildtype mice. Notably, escape latency of the hidden platform test on water maze test was significantly greater in 5XFAD mice with BCCAO than in wild-type mice with BCCAO. In water maze test, the hidden platform test reflects learning function, while the probe trial reflects memory function. 25 Collectively, our results show that brief cerebral ischemiainduced learning impairment in 5XFAD mice to a greater extent than in wild-type mice, thereby indicating that AD mice are more susceptible to brief cerebral ischemia than wild-type mice. Moreover, brief cerebral ischemia caused the reduction of hippocampal CA1 neuronal cell in 5XFAD mice more than in wild-type mice, indicating that AD mice show more vulnerability of hippocampal neuronal cells to brief ischemia than wild-type mice. These observations suggest that transient brief cerebral ischemia might be involved in the progression of cognitive dysfunction and hippocampal neuronal damage in AD. Taken together with the fact that hippocampus is most involved in cognitive function estimated by water maze test, 25 the increased cognitive impairment in 5XFAD mice subjected to BCCAO appears to be at least partially mediated by hippocampal neuronal damage. Our observations indicating susceptibility to transient cerebral ischemia of 5XFAD mice are consistent with the previous reports on different mouse models of AD [6] [7] [8] but are inconsistent with the report on APP/PS1 AD model mice 6 showing no genotype difference in susceptibility to brain ischemia. This discrepancy between our present findings and the findings by Kemppainen et al. seems to be accounted for by the difference in animal model, age, the way of brain ischemia, duration of brain ischemia, etc.
Blood-brain barrier disruption and oxidative stress play a central role in the development of neuronal damage and cognitive dysfunction in AD. 1, 2, 24, 26 Of note are the observations that brief cerebral ischemia significantly caused blood-brain barrier disruption in 5XFAD mice but not in wild-type mice and also tended to increase hippocampal oxidative stress in 5XFAD mice but not in wild-type mice. Collectively, these findings suggest that greater cognitive impairment and greater reduction of hippocampal neuronal cells induced by brief cerebral ischemia in 5XFAD mice than in wild-type mice seems to be at least in part mediated by greater blood-brain barrier disruption and greater oxidative stress in 5XFAD mice.
An emerging evidence supports the notion that reninangiotensin system, a key causal factor of hypertension and cardiovascular diseases, is potentially associated with the pathogenesis of AD and cognitive dysfunction. 10, 27, 28 The components and receptors of renin-angiotensin system exists within the brain tissue, and angiotensin II, the bioactive product of renin-angiotensin system, can exert various harmful effects such as the enhancement of oxidative stress and inflammation, and the impairment of cerebral blood flow regulation. 10, 27, 28 Experimental works show that reninangiotensin system blockers prevent cognitive impairment in various animal models including AD mouse model 11, [14] [15] [16] 29, 30 Figure 8. Number of neuronal cells in brain cortex of each group of 5XFAD mice and WT mice. The rectangle boxes within the whole brain (upper representative photograph) indicate cortical area in which the neuronal cell numbers were counted. Values are means ± SEM. n = 11 in WT-Sham, n = 12 in WT-BCCAO, n = 10 in 5XFAD-Sham, n = 10 in 5XFAD-BCCAO, n = 10 in 5XFAD-BCCAO + Olm. Statistical significance was tested with 1-way ANOVA followed by a post hoc Tukey's multiple comparison test between each group. Abbreviations: ANOVA, analysis of variance; BCCAO, group subjected to bilateral common carotid arterial occlusion; BCCAO + Olm, group subjected to bilateral common carotid arterial occlusion and treated with olmesartan; Sham, sham-operated group; WT, wild-type.
and they protect against ischemic brain damage. 7, [17] [18] [19] [20] [21] Furthermore, recent cohort study 12, 13 or case-control analysis 5 suggests that ARB might reduce the incidence of AD and the progression of cognitive decline. These previous findings encouraged us to hypothesize that angiotensin AT1 receptor may be involved in brief cerebral ischemia-induced cognitive dysfunction in AD. To test our hypothesis, we examined the effect of olmesartan, an AT1 receptor blocker, on cognitive dysfunction and brain injury in 5XFAD mice subjected to transient brief cerebral ischemia. Olmesartan is reported to ameliorate cognitive impairment in AD mouse model (APP23 mice) 14 and attenuate brain damage induced by brain ischemia. 17, 18 However, it remains to be determined whether ARBs including olmesartan exert beneficial effect Values are means ± SEM. n = 11 in WT-Sham, n = 12 in WT-BCCAO, n = 10 in 5XFAD-Sham, n = 9 in 5XFAD-BCCAO, n = 10 in 5XFAD-BCCAO + Olm. Statistical significance was tested with 1-way ANOVA followed by a post hoc Tukey's multiple comparison test between each group. Scale bar = 2 mm. Abbreviations: ANOVA, analysis of variance; BCCAO, group subjected to bilateral common carotid arterial occlusion; BCCAO + Olm, group subjected to bilateral common carotid arterial occlusion and treated with olmesartan; Sham, shamoperated group; WT, wild-type. Values are means ± SEM. In (a), n = 11 in WT-Sham, n = 11 in WT-BCCAO, n = 10 in 5XFAD-Sham, n = 9 in 5XFAD-BCCAO, n = 10 in 5XFAD-BCCAO + Olm. In (b), n = 11 in WT-Sham, n = 12 in WT-BCCAO, n = 10 in 5XFAD-Sham, n = 10 in 5XFAD-BCCAO, n = 10 in 5XFAD-BCCAO + Olm. In (a), statistical significance was tested with 1-way ANOVA followed by a post hoc Tukey's multiple comparison test between each group. In (b), statistical significance was tested with Kruskal-Wallis test followed by a post hoc Dunn's multiple comparison test between each group. Scale bar = 50 μm. Abbreviations: ANOVA, analysis of variance; BCCAO, group subjected to bilateral common carotid arterial occlusion; BCCAO + Olm, group subjected to bilateral common carotid arterial occlusion and treated with olmesartan; Sham, sham-operated group; WT, wild-type. on combined mouse model of AD and brain ischemia. We found that olmesartan posttreatment of 5XFAD mice with transient brief cerebral ischemia significantly prevented cognitive impairment and anxiety, and also significantly prevented the decrease in hippocampal neuronal cell number, without affecting blood pressure. These results show that brief cerebral ischemia-induced cognitive dysfunction and hippocampal neuronal cell damage in 5XFAD mice are at least partially attributed to AT1 receptor. Interestingly, olmesartan posttreatment significantly prevented ischemiainduced blood-brain barrier disruption and increase in hippocampal oxidative stress in 5XFAD mice. Collectively, our present findings suggest that AT1 receptor appears to be responsible for cognitive impairment and hippocampal neuronal cell damage in 5XFAD mice received mild cerebral ischemia, through blood-brain barrier disruption and enhancement of oxidative stress.
Cerebral vascular reactivity is one of the important factors regulating cerebral blood flow, thereby potentially affecting Aβ clearance or cognitive function. Therefore, in the present study, we compared cerebral vascular reactivity between all groups of 5XFAD mice and wild-type mice, by measuring the increase in cerebral blood flow induced by acetazolamide injection. We found no significant difference in cerebral vascular reactivity between 5XFAD mice and wild-type mice, regardless of transient cerebral ischemia. Furthermore, to examine whether brief cerebral ischemia or AT1 receptor blockade can affect cerebral Aβ deposition in 5XFAD mice, we measured cerebral Aβ deposition in each group of mice. We found that cerebral Aβ deposition was not significantly affected by brief cerebral ischemia or olmesartan, thereby suggesting that the condition of brief cerebral ischemia employed in this work and posttreatment with AT1 receptor blocker did not significantly affect Aβ clearance. Therefore, neither cerebral vascular reactivity nor Aβ clearance seems to participate in the mechanism underlying brief cerebral ischemia-induced cognitive impairment and brain injury in 5XFAD mice observed in this work. However, further study Values are means ± SEM. n = 6 in WT-Sham, n = 6 in WT-BCCAO, n = 6 in 5XFAD-Sham, n = 6 in 5XFAD-BCCAO, n = 6 in 5XFAD-BCCAO + Olm. Statistical significance was tested with Kruskal-Wallis test followed by a post hoc Dunn's multiple comparison test between each group. Scale bar = 100 µm. Abbreviations: BCCAO, group subjected to bilateral common carotid arterial occlusion; BCCAO + Olm, group subjected to bilateral common carotid arterial occlusion and treated with olmesartan; Sham, sham-operated group; WT, wild-type. is needed to define the potential role of cerebral vascular reactivity or Aβ clearance in cognitive impairment and brain injury in AD.
Study limitation
There are several study limitations in this study. First, many drugs have been reported to be effective in rodent models of AD, and all of them have failed in clinical trials. Therefore, it is unclear whether our present preclinical findings are of translational value. Second, the protocol chosen is not complete, because the effect of olmesartan on wild-type mice with BCCAO is not examined in the present study. However, the main purpose of this work was to examine the role of AT1 receptor in combined model of AD and brain ischemia. Third, the present work did not allow us to elucidate the detailed mechanism underlying oxidative stress. Further study is required to elucidate the potential contribution of oxidative stress-generating enzymes, antioxidants, or bloodbrain barrier disruption to oxidative stress in AD. Fourth, the significance of cortex in the present findings is not elucidated in the present work, although hippocampus is most involved in cognitive function estimated by water maze test.
In conclusion, by using 5XFAD mice, a useful mouse model of AD, we obtained the evidence that transient brief cerebral ischemia exacerbated cognitive dysfunction and hippocampal neuronal cell damage in AD mice more than in wild-type mice, indicating more vulnerability to brief cerebral ischemia in AD mice than in wild-type mice. Furthermore, we found that AT1 receptor is partially involved in more vulnerability to brief ischemia in AD mice, through disruption of bloodbrain barrier and enhancement of oxidative stress. Thus, our present work provided a novel insight into the mechanism responsible for link between cerebral ischemia and AD.
SUPPLEMENTARY MATERIAL
Supplementary materials are available at American Journal of Hypertension (http://ajh.oxfordjournals.org). Values are means ± SEM. n = 11 in WT-Sham, n = 12 in WT-BCCAO, n = 10 in 5XFAD-Sham, n = 9 in 5XFAD-BCCAO, n = 10 in 5XFAD-BCCAO + Olm. Statistical analysis was performed by 2-factor ANOVA with repeated measures followed by a post hoc Tukey's multiple comparison test between each group. Abbreviations: ANOVA, analysis of variance; BCCAO, group subjected to bilateral common carotid arterial occlusion; BCCAO + Olm, group subjected to bilateral common carotid arterial occlusion and treated with olmesartan; Sham, sham-operated group; WT, wild-type.
